Stereotactic ablative radiotherapy (SABR) for early stage, non-small cell lung cancer (NSCLC): two year clinical outcome data from the Oxford Cancer Centre (OCC). (January 2020) - Pascal, L.; O'Cathail, S.; Higgins, G.; Ajzensztejn, D.; Stuart, R.; Panakis, N.